EU funds trial for preemie insulin

Israel’s Elgan Pharma (see here previously) has been awarded a 2.36 million euros grant by the European Innovation Council. It will support a Phase III study of its ELGN-GL oral insulin-based formulation that helps the development of a preemie’s gastrointestinal (GI) system.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *